Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Search Results

Search by objective public record fields.

Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results are retrieved from ClinicalTrials.gov and synchronized into the directory. Search pages remain noindex by default.

Clear filters
ClinicalTrials.gov public records Last synced Sep 10, 2026, 4:38 PM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 1–24 of 323 matching trials from the live ClinicalTrials.gov search.
Local D1 index available.
Filters: Condition: Obliterative Bronchiolitis Clear all
Completed Phase 3 Interventional Results available

A Phase 3 Study of Ibrutinib (PCI-32765) Versus Ofatumumab in Patients With Relapsed or Refractory Chronic Lymphocytic Leukemia

NCT01578707
View directory record Official record
Conditions
Relapsed or Refractory Chronic Lymphocytic Leukemia, Small Lymphocytic Lymphoma
Interventions
ofatumumab, ibrutinib
Drug
Lead sponsor
Pharmacyclics LLC.
Industry
Eligibility
18 Years and older
Enrollment
391 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2012 – 2018
U.S. locations
25
States / cities
La Jolla, California • Los Angeles, California • Santa Maria, California + 20 more
Source: ClinicalTrials.gov public record
Updated Dec 17, 2019 · Synced Sep 10, 2026, 4:38 PM EDT
Completed Not applicable Interventional Results available

A Prospective Multicenter Longitudinal Cohort Study of the Mymobility Platform

NCT03737149
View directory record Official record
Conditions
Osteoarthritis, Knee, Osteoarthritis, Hip
Interventions
mymobility with Apple Watch
Other
Lead sponsor
Zimmer Biomet
Industry
Eligibility
18 Years and older
Enrollment
6,559 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2018 – 2025
U.S. locations
26
States / cities
Fremont, California • Irvine, California • Redwood City, California + 23 more
Source: ClinicalTrials.gov public record
Updated Mar 22, 2026 · Synced Sep 10, 2026, 4:38 PM EDT
Completed Phase 1 Interventional

Dose Escalation Study of ARQ 621 in Adult Patients With Metastatic Solid Tumors and Hematologic Malignancies

NCT00825487
View directory record Official record
Conditions
Metastatic Solid Tumors, Refractory/Relapsed Hematologic Malignancies
Interventions
ARQ 621
Drug
Lead sponsor
ArQule, Inc., a subsidiary of Merck Sharp & Dohme LLC, a subsidiary of Merck & Co., Inc. (Rahway, NJ USA)
Industry
Eligibility
18 Years and older
Enrollment
50 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2009 – 2011
U.S. locations
4
States / cities
Phoenix, Arizona • Santa Monica, California • Boston, Massachusetts + 1 more
Source: ClinicalTrials.gov public record
Updated Oct 18, 2011 · Synced Sep 10, 2026, 4:38 PM EDT
Recruiting Phase 2 Interventional

Belumosudil to Block Chronic Lung Allograft Dysfunction (CLAD) in High Risk Lung Transplant Recipients

NCT06476132
View directory record Official record
Conditions
Lung Transplant
Interventions
Belumosudil, Placebo for Belumosudil
Drug
Lead sponsor
National Institute of Allergy and Infectious Diseases (NIAID)
NIH
Eligibility
12 Years and older
Enrollment
234 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2025 – 2027
U.S. locations
11
States / cities
Los Angeles, California • Palo Alto, California • Baltimore, Maryland + 8 more
Source: ClinicalTrials.gov public record
Updated Aug 9, 2026 · Synced Sep 10, 2026, 4:38 PM EDT
Terminated Phase 1Phase 2 Interventional Results available

Glasdegib for Chronic Graft-Versus-Host Disease

NCT04111497
View directory record Official record
Conditions
Chronic Graft Versus Host Disease, Fasciitis
Interventions
Glasdegib
Drug
Lead sponsor
Fred Hutchinson Cancer Center
Other
Eligibility
18 Years and older
Enrollment
15 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2019 – 2023
U.S. locations
3
States / cities
Durham, North Carolina • Salt Lake City, Utah • Seattle, Washington
Source: ClinicalTrials.gov public record
Updated Oct 28, 2024 · Synced Sep 10, 2026, 4:38 PM EDT
Recruiting Not applicable Interventional Accepts healthy volunteers

Mobile Health Self-Management and Support System for Chronic and Complex Health Conditions

NCT02592291
View directory record Official record
Conditions
Spinal Cord Injuries, Cerebral Palsy, Spinal Dysraphism, Brain Injuries, Spina Bifida, Traumatic Brain Injury
Interventions
MHealth
Device
Lead sponsor
University of Pittsburgh
Other
Eligibility
12 Years and older
Enrollment
160 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2019 – 2026
U.S. locations
1
States / cities
Pittsburgh, Pennsylvania
Source: ClinicalTrials.gov public record
Updated Sep 2, 2026 · Synced Sep 10, 2026, 4:38 PM EDT
Terminated Phase 4 Interventional Results available

Safety And Efficacy Study Of Bosutinib In Patients With Philadelphia Chromosome Positive Chronic Myeloid Leukemia Previously Treated With One Or More Tyrosine Kinase Inhibitors

NCT02228382
View directory record Official record
Conditions
Previously Treated PH + CML
Interventions
Bosutinib
Drug
Lead sponsor
Pfizer
Industry
Eligibility
18 Years and older
Enrollment
163 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2014 – 2020
U.S. locations
13
States / cities
Los Angeles, California • Deerfield Beach, Florida • Miami, Florida + 6 more
Source: ClinicalTrials.gov public record
Updated Dec 29, 2021 · Synced Sep 10, 2026, 4:38 PM EDT
Completed Not applicable Interventional

Transplant Optimization Using Functional Imaging

NCT02364674
View directory record Official record
Conditions
Bronchiolitis Obliterans, Lung Transplant Rejection
Interventions
High Resolution Computed Tomography scan
Radiation
Lead sponsor
FLUIDDA nv
Industry
Eligibility
18 Years and older
Enrollment
8 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2015 – 2017
U.S. locations
2
States / cities
New York, New York • Gibson, Pennsylvania
Source: ClinicalTrials.gov public record
Updated Mar 28, 2017 · Synced Sep 10, 2026, 4:38 PM EDT
Completed Phase 1Phase 2 Interventional Results available

Using Donor Stem Cells and Alemtuzumab to Prevent Organ Rejection in Kidney Transplant Patients

NCT00183248
View directory record Official record
Conditions
Kidney Transplantation, Kidney Disease, Kidney Failure
Interventions
Alemtuzumab, Mycophenolate mofetil, Sirolimus, Tacrolimus, Donor bone marrow stem cell infusion, Kidney transplant
Drug · Procedure
Lead sponsor
University of Miami
Other
Eligibility
18 Years to 65 Years
Enrollment
9 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2004 – 2009
U.S. locations
1
States / cities
Miami, Florida
Source: ClinicalTrials.gov public record
Updated Oct 1, 2012 · Synced Sep 10, 2026, 4:38 PM EDT
Completed Phase 1Phase 2 Interventional

Phase 1/2 Dose Finding and Safety Study of Ibrutinib in Pediatric Subjects With Chronic Graft Versus Host Disease (cGVHD)

NCT03790332
View directory record Official record
Conditions
Chronic Graft Versus Host Disease
Interventions
Ibrutinib
Drug
Lead sponsor
Pharmacyclics LLC.
Industry
Eligibility
1 Year to 21 Years
Enrollment
59 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2018 – 2025
U.S. locations
20
States / cities
Duarte, California • San Diego, California • San Francisco, California + 17 more
Source: ClinicalTrials.gov public record
Updated Oct 20, 2025 · Synced Sep 10, 2026, 4:38 PM EDT
Recruiting Phase 1 Interventional

A Study to Evaluate the Safety of a Delivery Device for Administering LCTOPC1 in Participants With Spinal Cord Injury

NCT06841770
View directory record Official record
Conditions
Spinal Cord Injury Cervical, Spinal Cord Injury Thoracic, Spinal Cord Injury, Acute, Spinal Cord Injury, Spinal Cord Injury, Chronic
Interventions
OPC1
Biological
Lead sponsor
Lineage Cell Therapeutics, Inc.
Industry
Eligibility
18 Years to 65 Years
Enrollment
10 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2025 – 2037
U.S. locations
2
States / cities
Downey, California • La Jolla, California
Source: ClinicalTrials.gov public record
Updated Feb 11, 2026 · Synced Sep 10, 2026, 4:38 PM EDT
Not listed Not applicable Interventional Accepts healthy volunteers

tDCS as an Adjuvant to Intensive Speech Therapy for Chronic Post Stroke Aphasia

NCT02801864
View directory record Official record
Conditions
Aphasia, Language
Interventions
Real tDCS, Sham tDCS, Intensive Speech Therapy
Device · Other
Lead sponsor
Austin Speech Labs
Other
Eligibility
20 Years to 85 Years
Enrollment
6 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2016 – 2019
U.S. locations
1
States / cities
Austin, Texas
Source: ClinicalTrials.gov public record
Updated Jul 1, 2017 · Synced Sep 10, 2026, 4:38 PM EDT
Completed Phase 2 Interventional Results available

Rituximab for the Primary Treatment of Denovo Extensive Chronic Graft Versus Host Disease (GVHD)

NCT01161628
View directory record Official record
Conditions
Chronic Graft-versus-host Disease
Interventions
Rituximab
Drug
Lead sponsor
Northside Hospital, Inc.
Other
Eligibility
18 Years to 75 Years
Enrollment
25 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2011 – 2015
U.S. locations
1
States / cities
Atlanta, Georgia
Source: ClinicalTrials.gov public record
Updated Apr 19, 2016 · Synced Sep 10, 2026, 4:38 PM EDT
Completed No phase listed Observational

Immune Mediated Disorders After Allogeneic Hematopoietic Cell Transplantation

NCT01206309
View directory record Official record
Conditions
Graft vs Host Disease, Cutaneous Sclerosis, Bronchiolitis Obliterans
Interventions
Not listed
Lead sponsor
Fred Hutchinson Cancer Center
Other
Eligibility
Not listed
Enrollment
911 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2011 – 2016
U.S. locations
14
States / cities
Scottsdale, Arizona • Stanford, California • Tampa, Florida + 11 more
Source: ClinicalTrials.gov public record
Updated Oct 6, 2016 · Synced Sep 10, 2026, 4:38 PM EDT
Completed Phase 3 Interventional Results available

Efficacy + Safety of Liposome Cyclosporine A to Treat Bronchiolitis Obliterans Post Double Lung Transplant (BOSTON-2)

NCT03656926
View directory record Official record
Conditions
Bronchiolitis Obliterans, Chronic Rejection of Lung Transplant, Lung Transplant Rejection, Lung Transplant; Complications, Lung Transplant Failure and Rejection, Chronic Lung Allograft Dysfunction
Interventions
Liposomal Cyclosporine A, Standard of Care
Drug
Lead sponsor
Zambon SpA
Industry
Eligibility
18 Years and older
Enrollment
169 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2019 – 2024
U.S. locations
21
States / cities
Phoenix, Arizona • Los Angeles, California • Palo Alto, California + 16 more
Source: ClinicalTrials.gov public record
Updated Feb 9, 2026 · Synced Sep 10, 2026, 4:38 PM EDT
Completed Phase 3 Interventional Results available

A Study To Evaluate The Effects And Safety Of Treatment, Treatment Withdrawal, Followed By Re-Treatment With CP-690,550 In Subjects With Moderate To Severe Chronic Plaque Psoriasis

NCT01186744
View directory record Official record
Conditions
Psoriasis
Interventions
CP-690,550
Drug
Lead sponsor
Pfizer
Industry
Eligibility
18 Years and older
Enrollment
666 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2010 – 2013
U.S. locations
50
States / cities
Mobile, Alabama • Tucson, Arizona • Fremont, California + 33 more
Source: ClinicalTrials.gov public record
Updated Dec 25, 2018 · Synced Sep 10, 2026, 4:38 PM EDT
Completed No phase listed Observational

Prospective Evaluations of Infectious Complication in Lung Transplant Recipients

NCT00177918
View directory record Official record
Conditions
Disorder Related to Lung Transplantation, Bronchiolitis Obliterans
Interventions
Not listed
Lead sponsor
University of Pittsburgh
Other
Eligibility
18 Years and older
Enrollment
600 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2006 – 2026
U.S. locations
1
States / cities
Pittsburgh, Pennsylvania
Source: ClinicalTrials.gov public record
Updated Jan 11, 2026 · Synced Sep 10, 2026, 4:38 PM EDT
Terminated Phase 2 Interventional

Ruxolitinib for Early Lung Dysfunction After Hematopoietic Stem Cell Transplant

NCT04908735
View directory record Official record
Conditions
Hematopoietic Stem Cell Transplant (HSCT), Bronchiolitis Obliterans (BO)
Interventions
Ruxolitinib
Drug
Lead sponsor
Children's Hospital Medical Center, Cincinnati
Other
Eligibility
5 Years to 60 Years
Enrollment
7 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021 – 2025
U.S. locations
2
States / cities
Minneapolis, Minnesota • Cincinnati, Ohio
Source: ClinicalTrials.gov public record
Updated Apr 6, 2026 · Synced Sep 10, 2026, 4:38 PM EDT
Active, not recruiting Phase 2 Interventional

A Study to Evaluate the Safety and Efficacy of Axatilimab in Combination With Ruxolitinib in Participants With Newly Diagnosed Chronic Graft-Versus-Host Disease

NCT06388564
View directory record Official record
Conditions
Chronic Graft-versus-host-disease
Interventions
Axatilimab, Ruxolitinib, Corticosteroids
Drug
Lead sponsor
Incyte Corporation
Industry
Eligibility
12 Years and older
Enrollment
130 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2024 – 2029
U.S. locations
25
States / cities
Phoenix, Arizona • Duarte, California • Los Angeles, California + 18 more
Source: ClinicalTrials.gov public record
Updated May 21, 2026 · Synced Sep 10, 2026, 4:38 PM EDT
Completed Phase 3 Interventional Results available

A Study of Ruxolitinib vs Best Available Therapy (BAT) in Patients With Steroid-refractory Chronic Graft vs. Host Disease (GvHD) After Bone Marrow Transplantation (REACH3)

NCT03112603
View directory record Official record
Conditions
Graft-versus-host Disease (GVHD)
Interventions
Ruxolitinib, Extracorporeal photopheresis (ECP), Low-dose methotrexate (MTX), Mycophenolate mofetil (MMF), mechanistic Target of Rapamycin (mTOR) inhibitors (everolimus or sirolimus), Infliximab, Rituximab, Pentostatin, Imatinib, Ibrutinib
Drug
Lead sponsor
Incyte Corporation
Industry
Eligibility
12 Years and older
Enrollment
330 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2017 – 2022
U.S. locations
38
States / cities
Tucson, Arizona • Duarte, California • La Jolla, California + 28 more
Source: ClinicalTrials.gov public record
Updated Aug 11, 2025 · Synced Sep 10, 2026, 4:38 PM EDT
Completed Not applicable Interventional

Non-invasive Trigeminal and Vagus Nerve Stimulation for Stroke Subjects With Chronic Upper Extremity Deficits

NCT06288217
View directory record Official record
Conditions
Upper Extremity Paresis, Stroke, Chronic
Interventions
NeuraStasis Stimulator System (Non-Invasive Trigeminal and Vagus Nerve Stimulation), Upper Limb Rehabilitation, Sham Stimulation
Device · Other
Lead sponsor
NeuraStasis, Inc
Industry
Eligibility
30 Years to 85 Years
Enrollment
16 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2024 – 2025
U.S. locations
1
States / cities
Houston, Texas
Source: ClinicalTrials.gov public record
Updated Jun 1, 2026 · Synced Sep 10, 2026, 4:38 PM EDT
Recruiting Phase 2 Interventional

Repetitive Transcranial Magnetic Stimulation, a Form of Non-invasive Brain Stimulation, as a Possible Treatment for Post-stroke Fatigue.

NCT05584124
View directory record Official record
Conditions
Stroke, Stroke, Chronic, Fatigue
Interventions
High frequency repetitive transcranial magnetic stimulation, Sham repetitive transcranial magnetic stimulation
Device
Lead sponsor
VA Office of Research and Development
Federal
Eligibility
34 Years to 80 Years
Enrollment
60 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2023 – 2027
U.S. locations
1
States / cities
Decatur, Georgia
Source: ClinicalTrials.gov public record
Updated Apr 20, 2026 · Synced Sep 10, 2026, 4:38 PM EDT
Completed Not applicable Interventional Accepts healthy volunteers

Music-based Treatments and Pain: Underlying Mechanisms and the Beneficial Effects of Music-Based Treatments

NCT05578781
View directory record Official record
Conditions
Chronic Low-back Pain
Interventions
Music Therapy, Music Medicine, Control group
Behavioral
Lead sponsor
University of Washington
Other
Eligibility
18 Years and older
Enrollment
99 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2023 – 2024
U.S. locations
1
States / cities
Seattle, Washington
Source: ClinicalTrials.gov public record
Updated Aug 6, 2025 · Synced Sep 10, 2026, 4:38 PM EDT
Completed Not applicable Interventional

ED Physical Therapy for Chronic Low Back Pain

NCT05206630
View directory record Official record
Conditions
Low Back Pain
Interventions
ED Physical Therapy
Other
Lead sponsor
Northwestern University
Other
Eligibility
18 Years and older
Enrollment
128 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2022 – 2025
U.S. locations
1
States / cities
Chicago, Illinois
Source: ClinicalTrials.gov public record
Updated Oct 13, 2025 · Synced Sep 10, 2026, 4:38 PM EDT